We determined the percentage of immune cells positive for CD8 and CD3 surface proteins using IHC; PD-L1 staining on tumor cell and immune cell compartments using the Ventana SP142 assay (n = 62); infiltrating TCRβ diversity using hybridization capture method (CapTCR-seq5) (n = 45); and genomic profiles and tumor mutational burden (TMB) from CGP with the FoundationOne (F1) next-generation sequencing assay (n = 51) (Supplementary Table 1). This evidence concerns the gene CD274 and neoplasm.